Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 dose-escalation and cohort-expansion study of ERY974 in GPC3-positive advanced solid tumors
NL-OMON47296Phase 1Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Aug 2016
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of ERY974 in Nonhematologic neoplasms, gastric cancer (GC), gastroesophageal junction adenocarcinoma and 2 more (5 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Maximum tolerated dose, Preliminary anti-tumor activity and 2 more. Started Aug 2016; status: active, not recruiting.
02
Drugs
ERY974
03
Conditions
Nonhematologic neoplasmsgastric cancer (GC)gastroesophageal junction adenocarcinomahead and neck squamous cell carcinoma (HNSCC)Bone and soft tissue sarcoma
Beyond the preview
Go deeper on NL-OMON47296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47296.